Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

ypes of DLBCL, the activated B-cell (ABC) subtype and the germinal center (GC) subtype. We have enrolled 3 out of the planned 60 patients and expect to complete enrollment in the first quarter of calendar 2012. Other trials evaluating the combination of PCI-32765 with chemotherapy in DLBCL are under development.

A separate pilot study of PCI-32765 in patients with ABC subtype DLBCL is currently being conducted at the NIH Clinical Center. Thus far, 8 out of a planned 10 patients have been enrolled. While it is too early to report full results of this study, objective responses, including complete responses, have been observed. We anticipate that this study once completed will be submitted for presentation at the 2011 American Society of Hematology Meeting

-- Follicular Lymphoma (FL)
Updated results from the Phase IA study have shown an improvement in the objective response rate in follicular lymphoma. We are encouraged by this preliminary signal and are developing a Phase II program in this histology. We anticipate the initiation of a Phase II trial in follicular lymphoma in the first half of 2012.

-- Multiple Myeloma (MM)
Ongoing pre-clinical studies, both internally as well as through external collaborations, have suggested a vital role for Btk in both malignant plasma cells and osteoclasts, which are involved in the bone complications of this disease. Therefore, we believe that Btk represents a viable therapeutic target in MM, and we are developing a Phase II trial of PCI-32765 in MM, which we expect to initiate in early 2012.

"In February 2009 Pharmacyclics dosed the first patient with PCI-32765, a Bruton tyrosine kinase irreversible inhibitor. Bottom line, we have now dosed 230 patients across multiple hematologic histologies. The results have exceeded the expectations of most all involved to this point in time. We look forward to continued progress as well as playing a meaningful role in the comin
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 ... decades of experience, the domestic pharmaceutical industry is strong, ... manufacture products to high international standards. One ... known is in sub-Saharan Africa: Morocco has quietly become ... South Africa . Indeed, Moroccan pharma ...
(Date:7/31/2015)... Inc. (Nasdaq: SMLR ), a company that provides ... groups, today reported financial results for the second quarter ... second quarter of 2015, Semler reported continued progress with ... quarter revenue growth of 8%, and quarter over quarter ... 18%," said Doug Murphy-Chutorian, M.D., chief executive officer of ...
(Date:7/31/2015)... 31, 2015  Xencor, Inc. (NASDAQ: XNCR ), ... the treatment of autoimmune diseases, asthma and allergic diseases, ... S. Hata to its board of directors. ... corporate development is a tremendous asset to our board," ... executive officer of Xencor. "Xencor faces a range of ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Althea Technologies, Inc., a leading provider of development ... products, announced today that it has completed the ... filling line.  This line is located in Althea,s ... Diego. The expanded capacity complements existing prefilled syringe ...
... CHARLESTON, S.C., Oct. 19 The National Association ... of a $200,000 grant from Purdue Pharma L.P. ... Charleston, South Carolina. The grant is part of ... expansion and awareness of appropriately-designed state prescription drug ...
Cached Medicine Technology:Althea Technologies Announces the Installation of a High-Speed Prefilled Syringe Line 2NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs 2
(Date:7/31/2015)... ... ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and black diamond ... non-surgical fat reduction in New York. Due to its unparalleled level of experience ... Many patients travel to New York to get their non-surgical skin tightening and body ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Sculpted Contours Luxury ... CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in the United ... 2014 for treating the outer thighs. The original applicator required a 2 hour ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their ... VIPs at the 2015 Vans US Open of Surfing, July 25 through August 2 ... “no added sugar” on the market, is a natural choice given the Open’s commitment ...
(Date:7/31/2015)... Angeles, CA (PRWEB) , ... July 31, 2015 , ... ... surgeons and cosmetic experts gathered to see if they could reach a consensus on ... including breast augmentation and facelifts. Overall, the group reached 90 percent consensus on a ...
(Date:7/31/2015)... Dallas, Texas (PRWEB) , ... July 31, 2015 , ... ... Pet Sitter believes community involvement and support of animal welfare organizations is essential to ... for the third consecutive year in the National Association of Professional Pet Sitters (NAPPS) ...
Breaking Medicine News(10 mins):Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4
... circadian clock known as the suprachiasmatic nucleus, or SCN ... begins to decline by middle age. The study, whose senior ... the large number of older people who have difficulty sleeping ... a profound effect on circadian timing," said Block, a professor ...
... half of all Alzheimer,s disease cases could potentially be ... chronic medical conditions, according to a study led by ... San Francisco VA Medical Center. Analyzing data from ... participants, Barnes concluded that worldwide, the biggest modifiable risk ...
... PHILADELPHIA - Years after a single traumatic brain injury ... a new study, researchers from the Perelman School of ... disease-like neurodegeneration may be initiated or accelerated following a ... Over 1.7 million Americans suffer a traumatic brain injury ...
... , MONDAY, July 18 (HealthDay News) -- Genetically engineered human ... according to a new study. And, the researchers ... repair and function in these mice doubled that of control ... 20 weeks. "This study brings us one step closer ...
... JULY 18, 2011 Registration is now open for ... the Cardiovascular Research Foundation, which will return to San ... year, groundbreaking scientific advances in interventional cardiology presented at ... cause of death in the United States, is viewed ...
... levels of ,bad, cholesterol (LDL cholesterol) are a risk ... disease of the major arterial blood vessels that is ... stroke. Although the use of statins and the adoption ... decreased the incidence of and mortality from ASCVD, many ...
Cached Medicine News:Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 2Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 3Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 4Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 5Health News:Over half of Alzheimer's cases may be preventable, say researchers 2Health News:Single traumatic brain injury may prompt long-term neurodegeneration 2Health News:Human Stem Cells Used to Fix Damaged Mouse Heart 2Health News:Innovations in cardiovascular therapies and treatments will be presented at TCT 2011 2Health News:JCI online early table of contents: July 18, 2011 2Health News:JCI online early table of contents: July 18, 2011 3Health News:JCI online early table of contents: July 18, 2011 4Health News:JCI online early table of contents: July 18, 2011 5Health News:JCI online early table of contents: July 18, 2011 6Health News:JCI online early table of contents: July 18, 2011 7
... Used for temporary suprapubic urinary diversion and ... the bladder. The access sheath is left ... the catheter is introduced, the access sheath ... catheter support is included for external catheter ...
... The Reflotron Plus Chemistry Analyzer is an ... the quantitative determination of clinical chemistry parameters using ... of reflectance photometry and ensures rapid and reliable ... shown on a clear LC display and the ...
... B19 ASR contains primers and a FAM-labeled probe ... addition, the Parvo B19 ASR contains primers and ... sequence. This ASR requires an instrument that can ... SmartCycler System., The Cepheid Analyte Specific Reagent* (ASR) ...
... The Enterovirus ASR contains primers, a FAM-labeled probe ... to detect a 115 bp region of the ... can detect FAM, Alexa 532 and Texas Red ... Cepheid Analyte Specific Reagent* (ASR) program is comprised ...
Medicine Products: